Contents

Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (VIEW)

December 1, 2012

Clinical Trial

Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.

Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, Kirchhof B, Ho A, Ogura Y, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Groetzbach G, Sommerauer B, Sandbrink R, Simader C, Schmidt-Erfurth U.

Ophthalmology. 2012 Dec;119(12):2537-48.
Full text | Metrics.

Main finding: Intravitreal aflibercept dosed monthly or every 2 months after 3 initial monthly doses produced similar efficacy and safety outcomes as monthly ranibizumab.

 

  • Purpose: To compare monthly and every-2-month dosing of intravitreal aflibercept injection with with monthly ranibizumab in neovascular AMD.
  • Study type: Randomized controlled trial
  • Condition: CNV secondary to AMD

Participants: Active, subfoveal CNV secondary to AMD

 

  • n=2419

 

Intervention:

 

Group 1: Intravitreal Aflibercept 0.5mg monthly (AFLI 0.5q4)
Group 2: Intravitreal Aflibercept 2mg monthly (AFLI 2q4)
Group 3: Intravitreal Aflibercept 2mg q2monthly after 3 initial monthly doses (AFLI 2q8)
Group 4: Intravitreal Ranibizumab monthly (RAN)

Outcomes AFLI 0.5q4 AFLI 2q4 AFLI 2q8 RAN
Lost < 15 letters 95.1-95.6% 95.9-96.3% 95.1-95.6% 94.4%

Share This Article :

Updated on March 7th, 2022

Source Archive

© 2025 - sourceshed